Clinical Setbacks Prompt NGM Bio Lay Off One Third Of Its Staff, Founder Leaves

Comments
Loading...
  • NGM Biopharmaceuticals Inc NGM announced will be reducing its workforce by 75 staffers, or a third of the workforce, to extend its cash runway into 2025.
  • In its Q4 earnings, the company hinted at financial issues, narrowing its focus on oncology and intending to partner out some other programs in a cash-saving move.
  • The company estimates it will incur approximately $5.0 million in restructuring charges in connection with the restructuring, with the majority in the second quarter of 2023.
  • Founder Jin-Long Chen resigned as Chief Scientific Officer after 15 years with the company and as a Board member, effective April 4, 2023.
  • In an email to employees announcing the decision, CEO David Woodhouse said, "Raising capital has become increasingly difficult for companies in our industry over the last couple of years."
  • "In this regard, while we had hoped to be able to pursue a significant financing on the back of positive clinical data in 2022 following CATALINA, the clinical data we announced, unfortunately, did not support pursuing such a financing at that time."
  • CATALINA Phase 2 trial testing NGM's C3-inhibiting antibody in geographic atrophy flunked the primary endpoint, and the biotech's shares took a beating when it unveiled the results in October.
  • "Ongoing efforts to reduce our other operational expenses will not be sufficient on their own," Woodhouse wrote.
  • "While our strategy continues to include seeking business development transactions for one or more of our programs, even if we were to succeed in securing a deal or deals this year, we believe a restructuring would still be necessary to arrive at a more sustainable cash burn rate," he wrote.
  • Price Action: NGM shares are trading flat at $3.96 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!